Bionical Emas, a provider of clinical trial services, announced an exclusive global clinical trial supply agreement with Pharma Resources GmbH, German pharmaceutical company and marketing authorization holder, specialized in oncology. This strategic partnership marks Pharma Resources' entry into the clinical trial supply market and grants Bionical Emas exclusive rights to distribute its EU-marketed oncology injectables, including Fluorouracil, which is currently in critical shortage across Europe.
This collaboration strengthens Bionical Emas' position as a trusted supply partner and highlights its continued success in forging impactful global alliances. As the sole distributor, Bionical Emas will streamline access to Pharma Resources' oncology portfolio for pharmaceutical companies, CROs, and clinical trial providers worldwide.
The agreement comes at a crucial time, with 5-Fluorouracil shortages disrupting cancer treatments and clinical trials across Europe. Bionical Emas' global infrastructure and agile supply model will cut delivery times from months to weeks, ensuring faster, more reliable access to essential medications. By combining advanced demand forecasting with proactive inventory strategies, Bionical Emas and Pharma Resources are addressing long-standing supply chain challenges –accelerating trial timelines and improving flexibility for investigational sites.